PRTA - Prothena Corporation plc
Shares of Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have assigned a buy recommendation and one
Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) major shareholder William Scully purchased 125,000 shares of the business's stock in a transaction on Wednesday, October 7th. The stock was bought at an average cost of $8.40 per share, for a total transaction of $1,050,000.00. Following the purchase, the insider owned 439,000 shares of the company's
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both CorMedix (CRMD) and Prothena (PRTA). But which of these two stocks offers value investors a better bang for their buck right now?
Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
Shares of Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have assigned a buy
DUBLIN, Ireland--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Prothena (PRTA). But which of these two companies is the best option for those looking for undervalued stocks?
Prothena beat adjusted Q2 loss estimates, reaffirmed 2026 cash-use guidance and highlights partner pipeline progress as a key milestone decision nears.
Prothena (PRTA) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $1.86 per share a year ago.
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena reported financial results for the second quarter and first six months of 2026 and provided business highlights.
Shares of Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) passed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $9.46 and traded as low as $8.51. Prothena shares last traded at $8.75, with a volume of 647,643 shares trading hands. Wall Street Analyst Weigh In
Prothena shares climb as late-stage partnered programs advance, milestone payments strengthen finances and its neurodegenerative pipeline continues to expand.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Sarepta Therapeutics (SRPT) and Prothena (PRTA). But which of these two stocks is more attractive to value investors?
PRTA posted a Q1 profit as a $50M Novo Nordisk milestone payment boosted revenue and improved its 2026 cash outlook.
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena today reported financial results for the first quarter of 2026 and provided business highlights.
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announces Novo Nordisk obtains Fast Track Designation from the U.S. FDA for coramitug (PRX004) in ATTR amyloidosis with cardiomyopathy.
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena promoting Ms. Kingston to Chief Strategy Officer and Mr. Isaacs to General Counsel and Corporate Secretary. Mr. Malecek is departing in June.
The mean of analysts' price targets for Prothena (PRTA) points to a 120.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena partners presented clinical data updates for prasinezumab for Parkinson's and BMS-986446 for Alzheimer's disease at AD/PD™ 2026.
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena earned a $50 million milestone from Novo Nordisk related to enrollment in the Phase 3 CLEOPATTRA trial evaluating coramitug for ATTR-CM.